1. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009; 20(3): 556-63.

2. Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol 2015; 39(4): 519-27.

3. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4): 383-91.

4. Alizadeh Sh, Moshfeghi K, Kalantari M, Ebrahimi Kh. Lymph-node involvement and tumor markers in patients with breast cancer. Arak Med Univ J 2010; 12(4): 44-50. [in Persian]

5. Albertson DG, Gene amplification in cancer, Trends Genetics 2006; 22(8): 447-55.

6. Pauley RJ, Gimotty PA, Pains TJ, Dawson PJ, Wolman SR. INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes. Breast Cancer Res Treat 1996; 37(1): 65-76.

7. Berns EM, Klijn JG, Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992; 28(2-3): 697-700.

8. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 2013; 3(8): a014217.

9. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18(19): 3004-16

10. Tansey WP. Mammalian MYC proteins and cancer. New J Sci 2014; 2014: 1-27.

11. Xu J, Chen Y, Olopade OI. MYC and breast cancer. Genes Cancer 2010; 1(6): 629-40.

12. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000; 83(12): 1688-95.

13. Schlotter CM, Vogt U, Boss U, Mersch B, Wassmann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003; 5(2): R30-6.

14. Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Fanyete IF, Nedelof PM, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 2003; 201(1): 75-82.

15. Al-Kuraya k, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. Prognostic relevance of gene amplification and coamplification in breast cancer. Cancer Res 2004; 64 (23): 8534-40.

16. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP. C-myc amplification in primary breast carcinomas and their local recurrences. J Clin Pathol 2006; 59(4): 424-8.

17. Rodriguez-pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, James M, et al. Myc amplification in breast cancer: a chromogenic in situ hybridization study. J Clin Path 2007; 60(9): 1017-23.

18. Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin Biochem 2001; 34(7): 557-62.

19. Sarbia M, Loberg Ch, Wolter M, Arjumand J, Heep H, Reifenberger G, et al. Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophaqus. Am J Pathol 1999; 155(4): 1027-32.

20. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A 1986; 83(13): 4834-8.

21. Watson PH, Safneck JR, Le K, Dubik D, Shiu RP, Relationship of c-myc Amplification to Progression of Breast Cancer From In Situ to Invasive Tumor and Lymph Node Metastasis. J Natl Cancer Inst 1993; 85(11): 902-7.

22. Chrzan P, Skokowski J, Karmolinski A, Pawelczyk T. Amplification of c-myc gene and overexpression of c-Myc protein in breast cancer and adjacent non-neoplastic tissue. Clin Biochem 2001; 34(7): 557-62.

23. Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 1999; 81(8): 1385-91.

24. Ismail MF, Aly MS, Khaled HM, Mohamed HM. Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer. Ger Med Sci 2009; 6: 7.

25. Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ, Amplification of c-myc Oncogene by Chromogenic and Fluorescence In Situ Hybridization in Archival Breast Cancer Tissue Array Samples. Lab Invest 2001; 81(11): 1545–51.

26. Tsuda H, Hirohashi S, Hirota T, Shimosato Y. Alterations in Copy Number of c‐erbB‐2 and c‐myc Proto‐oncogenes in Advanced Stage of Human Breast Cancer. Acta Pathol Jpn 1991; 41(1): 19-23.

27. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y. Amplification of c‐myc and c‐erbB‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance. Int J Cancer 1989; 44(5): 802-5.

28. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992; 28(2-3): 697-700.